Signatera for immunotherapy response monitoring

Signatera is a personalized blood test, designed to track mutations specific to each patient's tumor. Your doctor can use Signatera alongside imaging tests to better assess your response to immunotherapy and help identify if your cancer is progressing. Signatera is optimized to monitor molecular residual disease by detecting circulating tumor DNA, or ctDNA, which are small fragments of DNA released by cancer cells. Revolutionizing cancer care begins with revolutionary testing. Learn more at nateraoncology.com